Table 1.
RBD-J formulations prepared to assess the effect of antigen-adjuvant interactions on mouse immunogenicity and storage stability. Seven formulations (F1-F7) of RBD-J were prepared in various combinations with AH, AP, and CpG. The composition of each formulation and the percentage of RBD-J and CpG bound to AH or AP is displayed along with the concentration of antigen and adjuvants in each formulation and the dose subcutaneously injected in mice (Balb/c, 50 µl injection volume). Note that the target concentration of RBD-J in each formulation was the same (100 mcg/ml). *LOQ = 15%.
| |
|
% Bound to aluminum adjuvant |
Concentration (mcg/mL) |
Dose injected in mice (mcg) Injection volume = 50 µL |
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Formulation No. | Adjuvant | RBD-J | CpG 1018 | RBD-J | Aluminum adjuvant | CpG 1018 | RBD-J | Aluminum adjuvant | CpG 1018 | No. of mice |
| F1 | AH | 50 | - | 100 | 1500 | - | 5 | 75 | - | 9 |
| F2 | AH | 100 | - | 100 | 1500 | - | 5 | 75 | - | 9 |
| F3 | AH+CpG | 100 | 100 | 100 | 1500 | 600 | 5 | 75 | 30 | 9 |
| F4 | AP | <15* | - | 100 | 1500 | - | 5 | 75 | - | 9 |
| F5 | AP+CpG | <15* | 0 | 100 | 1500 | 600 | 5 | 75 | 30 | 9 |
| F6 | CpG | - | - | 100 | - | 600 | 5 | - | 30 | 9 |
| F7 | No adjuvant | - | - | 100 | - | - | 5 | - | - | 9 |